Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the WASF3 Regulatory Complex in Pancreatic Cancer Using Stapled Peptides.

Biochemistry·2026
Same author

Constrained peptide mimics of the LRRK2 C-terminal Helix inhibits its kinase activity.

Bioorganic chemistry·2026
Same author

Extracellular Vesicle-Mediated Delivery of Constrained Peptides Disrupts the Pathogenic Interaction of LRRK2-FADD in Parkinson's Disease.

Journal of extracellular biology·2026
Same author

Anionic lipids direct efficient microfluidic encapsulation of stable and functionally active proteins in lipid nanoparticles.

Communications materials·2025
Same author

Development of an All-Hydrocarbon Stapled Peptide Targeting BRK1 in Triple-Negative Breast Cancer.

ACS medicinal chemistry letters·2025
Same author

Redox regulation and dynamic control of brain-selective kinases BRSK1/2 in the AMPK family through cysteine-based mechanisms.

eLife·2025

Related Experiment Video

Updated: Sep 26, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K

In Silico Optimized Stapled Peptides Targeting WASF3 in Breast Cancer.

Ameya J Limaye1, George N Bendzunas1, Matthew K Whittaker1

  • 1Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, Georgia 30602, United States.

ACS Medicinal Chemistry Letters
|April 22, 2022
PubMed
Summary

A new peptide, WAHMIS-2, disrupts the WASF3-WRC complex, inhibiting breast cancer cell motility and invasion. This targeted approach offers a promising strategy for suppressing cancer metastasis.

More Related Videos

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation
11:09

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation

Published on: August 1, 2018

10.9K
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.2K

Related Experiment Videos

Last Updated: Sep 26, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K
Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation
11:09

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation

Published on: August 1, 2018

10.9K
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.2K

Area of Science:

  • Molecular biology
  • Cell biology
  • Cancer research

Background:

  • Wiskott-Aldrich Syndrome Protein Family (WASF) members, particularly WASF3, are crucial regulators of actin dynamics.
  • WASF3 is implicated in breast cancer metastasis and invasion through its role in the WASF Regulatory Complex (WRC).
  • The WRC, comprising WASF3, CYFIP, NCKAP, ABI, and BRK1, controls actin nucleation, and its aberrant function drives cancer progression.

Purpose of the Study:

  • To develop a novel therapeutic strategy targeting the WRC to inhibit breast cancer metastasis.
  • To design and evaluate a second-generation WASF3 mimetic peptide, WAHMIS-2, for its ability to disrupt the WASF3-WRC interaction.

Main Methods:

  • Structure-guided design, homology modeling, and in silico optimization were employed to create WAHMIS-2.
  • WAHMIS-2 was assessed for its ability to permeate cells and inhibit cell motility, invasion, and MMP9 expression.
  • Comparative analysis with a predecessor peptide, WAHM1, was performed.

Main Results:

  • WAHMIS-2 effectively permeates cancer cells.
  • WAHMIS-2 demonstrated enhanced potency in inhibiting cell motility, invasion, and MMP9 expression compared to WAHM1.
  • The peptide successfully disrupts the binding of WASF3 to the WRC.

Conclusions:

  • Targeted disruption of the WASF3-WRC complex using WAHMIS-2 is a viable strategy for suppressing breast cancer metastasis.
  • WAHMIS-2 represents a promising therapeutic candidate for inhibiting cancer cell motility and invasion.
  • Further investigation into WAHMIS-2 could lead to novel treatments for metastatic breast cancer.